Merck
Q2 2023 Earnings Call
Aug 01, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Thank you for standing by. Welcome to the Merck & Co. Q2 sales and earnings conference call. All participants are in a listen-only mode until the question-and-answer session of today's conference.
[Operator instructions] This call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Peter Dannenbaum, vice president, investor relations.
Sir, you may begin.
Peter Dannenbaum -- Vice President, Investor Relations
Thank you, Cedric, and good morning, everyone. Welcome to Merck's second-quarter 2023 conference call. Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dr. Dean Li, president of Merck Research Labs.
Before we get started, I'd like to point out a few items. You will see that we have items in our GAAP results such as acquisition-related charges, restructuring costs, and certain other items. You should note that we have excluded these from our non-GAAP results and provide a reconciliation in our press release. I would like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision of the United States Private Securities Litigation Reform Act of 1995.
Such statements are made based on the current beliefs of Merck's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A in the 2022 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck undertakes no obligation to publicly update any forward-looking statements.
During today's call, a slide presentation will accompany our speakers' prepared remarks. These slides, along with the earnings release, today's prepared remarks and our SEC filings are all posted to the Investor Relations section of Merck's website. With that, I'd like to turn the call over to Rob.
Rob Davis -- Chairman and Chief Executive Officer
Thanks, Peter. Good morning, and thank you for joining today's call. We continue to make great progress in bringing forward-compelling science to help address the world's most urgent unmet medical needs. Thanks to the unwavering commitment and discipline of our global teams, we're advancing our innovative pipeline and executing operationally in support of our key growth drivers.